Is Adjuvant Radiotherapy Effective in Intermediate-risk Surgical Stage I Endometrial Cancer?
Objective: To better understand the potential risks and benefits of adjuvant radiotherapy in patients with intermediate-risk surgical stage I endometrial cancer. Materials and Methods: A retrospective chart review identified 55 patients with endometrial carcinoma stage IA grade 3, stage IB grade 2,...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2004-06-01
|
| Series: | Taiwanese Journal of Obstetrics & Gynecology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1028455909600644 |
| _version_ | 1818270712301879296 |
|---|---|
| author | Hung-Chuan Yu Chi-Mou Juang Ching-Ying Huang Nae-Fang Twu Ming-Shyen Yen |
| author_facet | Hung-Chuan Yu Chi-Mou Juang Ching-Ying Huang Nae-Fang Twu Ming-Shyen Yen |
| author_sort | Hung-Chuan Yu |
| collection | DOAJ |
| description | Objective: To better understand the potential risks and benefits of adjuvant radiotherapy in patients with intermediate-risk surgical stage I endometrial cancer.
Materials and Methods: A retrospective chart review identified 55 patients with endometrial carcinoma stage IA grade 3, stage IB grade 2, and stage IC grade 1, treated at Taipei Veterans General Hospital, Taipei, Taiwan, between 1980 and 2001. The median duration of follow-up was 47 months, and patient age ranged from 34 to 82 years. One patient had stage IA grade 3 cancer, 52 had stage IB grade 2, and two had stage IC grade 1. Thirty-four patients underwent surgery alone and 21 underwent surgery plus radiotherapy. We determined the outcome of adjuvant treatment with postoperative pelvic radiotherapy or surgery alone, comparing locoregional control, overall survival, and treatment-related morbidity.
Results: There was no statistically significant survival difference between the surgery-only and surgery-plus- radiation groups (p = 0.5927). The 5-year overall survival rates were 97% and 95%, respectively. Univariate analysis of prognostic factors showed that only hypertension influenced survival rate (p < 0.0344). The overall recurrence rate was 3.6% (2/55).
Conclusion: The survival rate was high and the relapse rate was low in intermediate-risk surgical stage I endometrial cancer patients. Radiotherapy may be reserved for recurrence. |
| first_indexed | 2024-12-12T21:14:38Z |
| format | Article |
| id | doaj.art-2f20cdad124a480d968acc1269d21689 |
| institution | Directory Open Access Journal |
| issn | 1028-4559 |
| language | English |
| last_indexed | 2024-12-12T21:14:38Z |
| publishDate | 2004-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Taiwanese Journal of Obstetrics & Gynecology |
| spelling | doaj.art-2f20cdad124a480d968acc1269d216892022-12-22T00:11:47ZengElsevierTaiwanese Journal of Obstetrics & Gynecology1028-45592004-06-0143210110610.1016/S1028-4559(09)60064-4Is Adjuvant Radiotherapy Effective in Intermediate-risk Surgical Stage I Endometrial Cancer?Hung-Chuan YuChi-Mou JuangChing-Ying HuangNae-Fang TwuMing-Shyen YenObjective: To better understand the potential risks and benefits of adjuvant radiotherapy in patients with intermediate-risk surgical stage I endometrial cancer. Materials and Methods: A retrospective chart review identified 55 patients with endometrial carcinoma stage IA grade 3, stage IB grade 2, and stage IC grade 1, treated at Taipei Veterans General Hospital, Taipei, Taiwan, between 1980 and 2001. The median duration of follow-up was 47 months, and patient age ranged from 34 to 82 years. One patient had stage IA grade 3 cancer, 52 had stage IB grade 2, and two had stage IC grade 1. Thirty-four patients underwent surgery alone and 21 underwent surgery plus radiotherapy. We determined the outcome of adjuvant treatment with postoperative pelvic radiotherapy or surgery alone, comparing locoregional control, overall survival, and treatment-related morbidity. Results: There was no statistically significant survival difference between the surgery-only and surgery-plus- radiation groups (p = 0.5927). The 5-year overall survival rates were 97% and 95%, respectively. Univariate analysis of prognostic factors showed that only hypertension influenced survival rate (p < 0.0344). The overall recurrence rate was 3.6% (2/55). Conclusion: The survival rate was high and the relapse rate was low in intermediate-risk surgical stage I endometrial cancer patients. Radiotherapy may be reserved for recurrence.http://www.sciencedirect.com/science/article/pii/S1028455909600644adjuvant radiotherapyendometrial cancer stage Iintermediate riskoverall survival |
| spellingShingle | Hung-Chuan Yu Chi-Mou Juang Ching-Ying Huang Nae-Fang Twu Ming-Shyen Yen Is Adjuvant Radiotherapy Effective in Intermediate-risk Surgical Stage I Endometrial Cancer? Taiwanese Journal of Obstetrics & Gynecology adjuvant radiotherapy endometrial cancer stage I intermediate risk overall survival |
| title | Is Adjuvant Radiotherapy Effective in Intermediate-risk Surgical Stage I Endometrial Cancer? |
| title_full | Is Adjuvant Radiotherapy Effective in Intermediate-risk Surgical Stage I Endometrial Cancer? |
| title_fullStr | Is Adjuvant Radiotherapy Effective in Intermediate-risk Surgical Stage I Endometrial Cancer? |
| title_full_unstemmed | Is Adjuvant Radiotherapy Effective in Intermediate-risk Surgical Stage I Endometrial Cancer? |
| title_short | Is Adjuvant Radiotherapy Effective in Intermediate-risk Surgical Stage I Endometrial Cancer? |
| title_sort | is adjuvant radiotherapy effective in intermediate risk surgical stage i endometrial cancer |
| topic | adjuvant radiotherapy endometrial cancer stage I intermediate risk overall survival |
| url | http://www.sciencedirect.com/science/article/pii/S1028455909600644 |
| work_keys_str_mv | AT hungchuanyu isadjuvantradiotherapyeffectiveinintermediaterisksurgicalstageiendometrialcancer AT chimoujuang isadjuvantradiotherapyeffectiveinintermediaterisksurgicalstageiendometrialcancer AT chingyinghuang isadjuvantradiotherapyeffectiveinintermediaterisksurgicalstageiendometrialcancer AT naefangtwu isadjuvantradiotherapyeffectiveinintermediaterisksurgicalstageiendometrialcancer AT mingshyenyen isadjuvantradiotherapyeffectiveinintermediaterisksurgicalstageiendometrialcancer |